Skip to main content

Day: March 9, 2023

Logan Ridge Finance Corporation Announces Fourth Quarter and Full Year 2022 Financial Results

Reports a Strong Fourth Quarter with Net Investment Income of $0.23 Per Share, Which Marks its Second Consecutive Quarter of Positive Net Investment Income and More Than Triples the Net Investment Income Reported in the Prior Quarter Restores Quarterly Distribution; Announces $0.18 Per Share Distribution for the First Quarter of 2023 Board of Directors Authorizes a $5.0 Million Share Repurchase Program NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — Logan Ridge Finance Corporation (“Logan Ridge”, “LRFC” or the “Company”) (Nasdaq: LRFC) announced today its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 HighlightsReported positive Net Investment Income (“NII”) of $0.6 million or $0.23 per share, which marks the Company’s second consecutive quarter of positive NII. Net asset value...

Continue reading

Oil-Dri Announces Record Sales for the Second Quarter and First Six-Months of Fiscal Year 2023

CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its second quarter and first six-months of fiscal year 2023.  Second Quarter Year to Date(in thousands, except per share amounts) Ended January 31, Ended January 31,  2023 2022 Change 2023 2022 ChangeConsolidated Results            Net Sales $101,669 $87,210 17 % $200,208 $169,670 18 %Net Income Attributable to Oil-Dri $3,856 $2,002 93 % $9,097 $2,587 252 %Net Income Attributable to Oil-Dri Excluding Landfill Modification† $5,833 $2,002 191 % $11,074 $2,587 328 %Earnings per Common Diluted Share $0.56 $0.28 100 % $1.34 $0.37 262 %Earnings per Common Diluted Share Excluding Landfill Modification† $0.85 $0.28 204 % $1.63 $0.37 341 %Business...

Continue reading

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

– On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening – – Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipated in Second Half of 2023; Trial Recruiting in the U.S. and Canada – – Anticipated Cash Runway Into Fourth Quarter 2024 Enables Execution Against Key Milestones – BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments. “We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome, and we anticipate initial data read-outs from...

Continue reading

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

— Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 — — Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 — — Clinical evidence building for differentiation of self-amplifying mRNA (samRNA) as a potential next-gen mRNA platform in infectious disease — — Cash, cash equivalents, marketable securities, and restricted cash of $185.2 million as of December 31, 2022 — — Gritstone to host conference call today at 4:30pm ET — EMERYVILLE, Calif., March 09, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS),...

Continue reading

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 – – Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months – – Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS®) Injection Procedure Using FDA-Approved XIPERE® – – Management to Host Webcast and Conference Call Today at 4:30 P.M. ET – ALPHARETTA, Ga., March 09, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate...

Continue reading

AvePoint Announces Fourth Quarter and Full Year 2022 Financial Results

Full year SaaS revenue of $117.2 million, representing 37% year-over-year growth, 46% adjusted for constant currencyFull year total revenue of $232.3 million, representing 21% year-over-year growth, 29% adjusted for constant currencyTotal ARR of $201.7 million, representing 27% year-over-year growth, 32% adjusted for FX impact JERSEY CITY, N.J., March 09, 2023 (GLOBE NEWSWIRE) — AvePoint (NASDAQ: AVPT), the most advanced platform to optimize SaaS operations and secure collaboration, today announced financial results for the fourth quarter and full year ended December 31, 2022.  “Our fourth quarter results were a strong close to 2022, highlighted by 32% ARR growth and 26% revenue growth, both adjusted for the impact of FX,” said Dr. Tianyi Jiang (TJ), CEO and Co-Founder of AvePoint. “Despite an uncertain macro environment, our strong...

Continue reading

New York Mortgage Trust Declares First Quarter 2023 Common Stock Dividend of $0.40 Per Share, and Preferred Stock Dividends

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.40 per share on shares of its common stock for the quarter ending March 31, 2023. The dividend will be payable on April 26, 2023 to common stockholders of record as of the close of business on March 20, 2023. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series D Preferred Stock”), 7.875% Series E Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series E Preferred Stock”), 6.875% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (“Series F Preferred Stock”) and 7.000% Series G Cumulative Redeemable...

Continue reading

Frequency Electronics, Inc. Announces Third Quarter Fiscal Year 2023 Financial Results

MITCHEL FIELD, N.Y., March 09, 2023 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is reporting revenues for the three- and nine-month periods of fiscal 2023, ended January 31, 2023, of approximately $10.6 million and $27.8 million, respectively, compared to revenues of $12.2 million and $38.1 million, respectively, for the same periods of fiscal 2022, ended January 31, 2022. Operating income for the third quarter of fiscal 2023 was $325,000 compared to an operating loss of $721,000 for the same period of fiscal 2022. Operating loss for the nine months ended January 31, 2023 was $5.1 million compared to an operating loss of $2.1 million for the nine months ended January 31, 2022. Net loss from operations for the three and nine months ended January 31, 2023 was $316,000 or ($0.03) per diluted...

Continue reading

REE Automotive, Ltd. Announces Date for Fourth Quarter 2022 Earnings Release and Conference Call

TEL-AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) — REE Automotive, Ltd. (NASDAQ: REE) (“REE” or the “Company”), an automotive technology company and provider of electric vehicle platforms and EVs, announced today that the Company will release its fourth quarter 2022 financial results before the NASDAQ market opens on Thursday, March 16, 2023. A webcast and conference call will be held on the same date at 8:30 a.m. Eastern time to review the Company’s results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investors section of the Company’s website at investors.ree.auto. Click here for webcast URL The conference call will be accessible domestically or internationally, by pre-registering in the link provided at investors.ree.auto. Upon registering,...

Continue reading

Nano Dimension Answers over 21 Questions of A Very Confused Shareholder, (a/k/a “Murchinson”) and Possibly More Perplexed “Mr. Marc Bistricer”

Video Clip, Addressing Misinformation, Fake Data and Manipulation of Truth Waltham, Mass., March 09, 2023 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, released today a video addressing misinformation by a confused shareholder. Click here to watch the video: https://youtu.be/3XMsQ-LNPc0 In this video, Nano Dimension’s Chairman and Chief Executive Officer Yoav Stern will provide clear and concise explanations, clear up any doubts and eradicate misconceptions. We believe that this initiative will promote transparency and reinforce our commitment to keeping our shareholders well-informed, rather than repetitively being exposed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.